Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as “non-resected” stage I/II and CNS-negative advanced-stage III/IV (70% of cases). We performed...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Patte, Catherine, Auperin, Anne, Gerrard, Mary, Michon, Jean, Pinkerton, Ross, Sposto, Richard, Weston, Claire, Raphael, Martine, Perkins, Sherrie L., McCarthy, Keith, Cairo, Mitchell S.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2007
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1852229/
https://ncbi.nlm.nih.gov/pubmed/17132719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-07-036673
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares